NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Paradigm Biopharmaceuticals to Return $2 Million of Funds to Obsidian Global

Paradigm Biopharmaceuticals Ltd-Agreement to Return US$2M to Obsidian

Paradigm Biopharmaceuticals - 2 Mln Convertible Notes Issued in Tranche 4 Drawdown to be Cancelled

Australia's Mesoblast Rises on FDA Approval for New Potency Assay for Commercial Ryoncil

Mesoblast - Receives FDA Approval for New Potency Assay for Commercial Ryoncil Product

Hexcel Poised to Continue to Benefit From its Widebody Aircraft Exposure, RBC Says

Actinogen Xanamia Pivotal Alzheimer’s Disease Trial Completes Final Patient Visit, with Topline Results on Track for November

Paradigm Biopharmaceuticals' Knee Osteoarthritis Study Fails to Reach Continuation Threshold

Prescient Therapeutics Raises Around AU$4.8 Million Via Share Purchase Plan, AU$1.2 Million in Shortfall Placement

Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million in Placement

Actinogen Medical Completes Final Patient Visit in Alzheimer's Therapy Trial; Shares Up 5%

Dimerix Receives AU$17 Million in Proceeds After Completing Initial Drawdown Under Non-Dilutive Funding Facility

Prescient Therapeutics - Raises A$4.8 Mln Via Spp and A$1.2 Mln in Placement

Prescient Therapeutics - Issue Price for Placement and Spp Shares Set at A$0.065 Per Share

Immuron Submits Coffee Microcaps Conference Presentation##

TC Energy Sells Mexico Natural Gas Pipeline to Esentia for $399.2 Million

Dimerix Ltd-Waiver of Listing Rule 10.1 Granted